Acute coronary syndromes (ACS) are characterized by a sudden reduction in blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Each year, an estimated more than 7 million people worldwide are diagnosed with ACS, including over 1 million patients hospitalized in the United States. Bevifibatide Citrate Injection (BETAGRIN) is indicated for the treatment of acute coronary syndromes.
